5-Alpha-reductase and the development of the human prostate

Indian Journal of Urology

Volumn 24, Issue 3, 2008, Pages 309-312

  Radmayr, C ^a   Lunacek, A ^a   Schwentner, C ^a   Oswald, J ^a   Klocker, H ^a   Bartsch, G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

5 Alpha reductase; Fetal development; Human prostate

Indexed keywords

EID: 50949087153     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.42610     Document Type: Review

References (23)

1. Dolder CR. Dutasteride: A dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia. Ann Pharmacother 2006;40:658-65.
2. Luu-The V. Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 2001;76:143-51.
3. Aumueller G, Eicheler W, Renneberg H, Adermann K, Vilja P, Forssmann WG. Immunocytochemical evidence for differential subcellular localization of 5 alpha-reductase isoenzymes in human tissues. Acta Anat 1996;156:241-52.
4. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward S W, et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 2004;92:221-36.
5. Thomas LN, Douglas RC, Vessey J P, Gupta R, Fontaine D, Norman RW, et al. 5 reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003;170:2019-25.
6. rd ed. Cambridge: Cambridge University Press; 2004. p. 347-74
7. Steers WD. 5 alpha reductase activity in the prostate. Urology 2001;58:17-24.
8. Lunacek A, Schwentner C, Oswald J, Fritsch H, Sergi H, Rittmaster T, et al. Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate development. J Urol 2007;178:716-21.
9. Kim KS, Liu W, Cunha GR, Russel DW, Huang H, Shapiro E, et al. Expression of the androgen receptor and 5alpha reductase type 2 in the developing human fetal penis and urethra. Cell Tissue Res 2002;307:145-53.
10. Thigpen AE, Silver RI, Guileyardo JM, Casey L, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5-reductase isoenzyme expression. J Clin Invest 1993;92:903-10.
11. Schwentner C, Oswald J, Lunacek A, Fritsch H, Deibl M, Bartsch G, et al. Loss of interstitial cells of cajal and gap junction protein connexin 43 at the vesicoureteral junction in children with vesicoureteral reflux. J Urol 2005;174:1981-6.
12. Berman DM, Tian H, Russell DW. Expression and regulation of steroid 5 alpha-reductase in the urogenital tract of the fetal rat. Mol Endocrinol 1995;9:1561-70.
13. Wilson JD, Leihy MW, Shaw G, Renfree MB. Androgen physiology: Unsolved problems at the millennium. Mol Cell Endocrinol 2002;198:1-5.
14. Auchus R. The backdoor-pathway to dihydrotestosterone. Trends Endocrinol Metab 2004;15:432-8.
15. Lunacek A, Oswald J, Schwentner C, Schlenck B, Horninger W, Fritsch H, et al. Growth curves of the fetal prostate based on three-dimensional reconstructions: A correlation with gestational age and maternal testosterone levels. BJU Int 2007;99:151-6.
16. Bartsch G, Rittmaster R, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002;19:413-25.
17. Bruchovsky N, Sadar MD, Akakura K, Goldenberg SL, Matsuoka K, Rennie PS. Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 1996;59:397-404.
18. Andersson S, Berman DM, Jenkins E P, Russel DW. Deletion of steroid 5 alpha -reductase 2 gene in male pseudohermaphroditism. Nature 1991;354:159-61.
19. Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5-alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002;198:51-9.
20. Radmayr C, Culig Z, Glatzl J, Neuschmid-Kaspar F, Bartsch G, Klocker H. Androgen receptor point mutations as the underlying molecular defect in two patients with androgen insensitivity syndrome. J Urol 1997;158:1553-6.
21. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brian S P, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231-9.
22. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24
23. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: Studies with alpha-ERKO and beta-ERKO mice. Cancer Res 2001;61:6089-97.